User profiles for DONG-WOOK KIM

DONG WOOK KIM

- Verified email at krict.re.kr - Cited by 84714

Dong Wook Kim

- Verified email at hanyang.ac.kr - Cited by 6416

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

…, TP Hughes, HM Kantarjian, DW Kim… - Blood, The Journal …, 2013 - ashpublications.org
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet …

[HTML][HTML] European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

…, TP Hughes, JJWM Janssen, HM Kantarjian, DW Kim… - Leukemia, 2020 - nature.com
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. …

[HTML][HTML] Ultrasonography diagnosis and imaging-based management of thyroid nodules: revised Korean Society of Thyroid Radiology consensus statement and …

…, SJ Jeon, SL Jung, DW Kim, EK Kim… - Korean journal of …, 2016 - ncbi.nlm.nih.gov
The rate of detection of thyroid nodules and carcinomas has increased with the widespread
use of ultrasonography (US), which is the mainstay for the detection and risk stratification of …

[HTML][HTML] Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

G Saglio, DW Kim, S Issaragrisil… - … England Journal of …, 2010 - Mass Medical Soc
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib.
We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients …

In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy

SC Kim, DW Kim, YH Shim, JS Bang, HS Oh… - Journal of controlled …, 2001 - Elsevier
Although the current clinical formulation of paclitaxel (Taxol ® ) has a promising clinical
activity against a wide variety of tumors, it has significant toxic side effects, some of which are …

Evidence for several waves of global transmission in the seventh cholera pandemic

A Mutreja, DW Kim, NR Thomson, TR Connor, JH Lee… - Nature, 2011 - nature.com
Vibrio cholerae is a globally important pathogen that is endemic in many areas of the world
and causes 3–5 million reported cases of cholera every year. Historically, there have been …

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

…, J Wang, JJ Kassack Ipiña, DW Kim… - Blood, The Journal …, 2012 - ashpublications.org
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …

[HTML][HTML] Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations

…, SL Jung, DW Kim, EK Kim, JY Kim… - Korean journal of …, 2011 - ncbi.nlm.nih.gov
The detection of thyroid nodules has become more common with the widespread use of
ultrasonography (US). US is the mainstay for detecting and making the differential diagnosis of …

[HTML][HTML] PKC-θ knockout mice are protected from fat-induced insulin resistance

JK Kim, JJ Fillmore, MJ Sunshine… - The Journal of …, 2004 - Am Soc Clin Investig
Insulin resistance plays a primary role in the development of type 2 diabetes and may be
related to alterations in fat metabolism. Recent studies have suggested that local accumulation …

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic …

NP Shah, HM Kantarjian, DW Kim, D Réa… - Journal of Clinical …, 2008 - ascopubs.org
Purpose Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against
unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with …